Announcements Trials
Browse Landscape

Phase

Phase 2 7Phase 3 5Phase 1 3Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Completed 3Withdrawn 2

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 1Myeloid 1

Conditions

Thrombocythemia, Essential 1Solid Cancers 1Polycythemia Vera 1Neoplasm of Uncertain Malignant Potential 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × peginterferon alfa-2a × Clear all
NCT02174172 2020-05-12

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Hoffmann-La Roche

Phase 1 Completed
158 enrolled

Solid Cancers

NCT02407080 2019-09-12

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

NCT00253474 2012-03-29

PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
36 enrolled
Other solid neoplasm

Neoplasm of Uncertain Malignant Potential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡